Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies

被引:174
作者
Ejima, Daisuke [1 ]
Tsumoto, Kouhei
Fukada, Harumi
Yumioka, Ryosuke
Nagase, Kazuo
Arakawa, Tsutomu
Philo, John S.
机构
[1] Ajinomoto Co Inc, Amino Sci Labs, Appl Res Dept, Kawasaki, Kanagawa 2108681, Japan
[2] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Kashiwa, Chiba 2778562, Japan
[3] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Osaka 5998531, Japan
[4] Alliance Prot Labs, Thousand Oaks, CA 91360 USA
关键词
antibody; acid treatment; conformation; aggregation; circular dichroism; sedimentation velocity; differential scanning calorimetry;
D O I
10.1002/prot.21243
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Exposure of antibodies to low pH is often unavoidable for purification and viral clearance. The conformation and stability of two humanized monoclonal antibodies (hIgG4-A and -B) directed against different antigens and a mouse monoclonal antibody (mIgG1) in 0.1M citrate at acidic pH were studied using circular dichroism (CD), differential scanning calorimetry (DSC), and sedimentation velocity. Near- and far-UV CD spectra showed that exposure of these antibodies to pH 2.7-3.9 induced only limited conformational changes, although the changes were greater at the lower pH. However, the acid conformation is far from unfolded or so-called molten globule structure. Incubation of hIgG4-A at pH 2.7 and 3.5 at 4 degrees C over the course of 24 h caused little change in the near-UV CD spectra, indicating that the acid conformation is stable. Sedimentation velocity showed that the hIgG4-A is largely monomeric at pH 2.7 and 3.5 as well as at pH 6.0. No time-dependent changes in sedimentation profile occurred upon incubation at these low pHs, consistent with the conformational stability observed by CD. The sedimentation coefficient of the monomer at pH 2.7 or 3.5 again suggested that no gross conformational changes occur at these pHs. DSC analysis of the antibodies showed thermal unfolding at pH 2.7-3.9 as well as at pH 6.0, but with decreased melting temperatures at the lower pH. These results are consistent with the view that the antibodies undergo limited conformational change, and that incubation at 4 degrees C at low pH results in no time-dependent conformational changes. Titration of hIgG4-A from pH 3.5 to 6.0 resulted in recovery of native monomeric proteins whose CD and DSC profiles resembled those of the original sample. However, titration from pH 2.7 resulted in lower recovery of monomeric antibody, indicating that the greater conformational changes observed at this pH cannot be fully reversed to the native structure by a simple pH titration.
引用
收藏
页码:954 / 962
页数:9
相关论文
共 25 条
[1]  
Birch J. R., 1995, P231
[2]   ALTERNATIVELY FOLDED STATES OF AN IMMUNOGLOBULIN [J].
BUCHNER, J ;
RENNER, M ;
LILIE, H ;
HINZ, HJ ;
JAENICKE, R ;
KIEFHABER, T ;
RUDOLPH, R .
BIOCHEMISTRY, 1991, 30 (28) :6922-6929
[3]   TEMPERATURE AND PH-DEPENDENCE OF IMMUNOGLOBULIN-G CONFORMATION [J].
CALMETTES, P ;
CSER, L ;
RAJNAVOLGYI, E .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1991, 291 (02) :277-283
[4]  
Cleland JL, 2001, J PHARM SCI, V90, P310, DOI 10.1002/1520-6017(200103)90:3<310::AID-JPS6>3.0.CO
[5]  
2-R
[6]  
CO MS, 2001, Patent No. 6228360
[7]   Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody [J].
Costantino, HR ;
Andya, JD ;
Nguyen, PA ;
Dasovich, N ;
Sweeney, TD ;
Shire, SJ ;
Hsu, CC ;
Maa, YF .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (11) :1406-1411
[8]  
FINK AL, 1995, ANNU REV BIOPH BIOM, V24, P495, DOI 10.1146/annurev.bb.24.060195.002431
[9]   NONRANDOM CONFORMATION OF A MOUSE IGG2A MONOCLONAL-ANTIBODY AT LOW PH [J].
JISKOOT, W ;
BLOEMENDAL, M ;
VANHAERINGEN, B ;
VANGRONDELLE, R ;
BEUVERY, EC ;
HERRON, JN ;
CROMMELIN, DJA .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1991, 201 (01) :223-232
[10]   Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor [J].
Kageyama, S ;
Yamamoto, H ;
Nagano, M ;
Arisaka, H ;
Kayahara, T ;
Yoshimoto, R .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 (01) :165-171